• Big Data for Breast Cancer 3

    MAP

    On February 1-2, 2018, Komen will continue the big data conversation by convening the BD4BC3 conference to take a deeper dive into how big data can be leveraged toward Komen’s Bold Goal to reduce the current number of breast cancer deaths by 50% in the U.S. by 2026.  The goals of this meeting are to leverage big data to identify breast cancer disparities and variances in care, and to improve the methods for aggregating and analyzing clinical, genomic and other sources of data for metastatic breast cancer patients.  By focusing on these topics, we hope to map out strategies that will unlock big data to save lives.  

    Overview


    Susan G. Komen® started the big data for breast cancer conversation in 2015 by convening BD4BC: Big Data for Breast Cancer at Rockefeller University in New York, NY. We subsequently convened BD4BC–West Coast Conference (BD4BC\WC) in 2017 in Menlo Park, CA. Both conferences were generously supported by the Robertson Foundation. The intent of those meetings was to explore the opportunities and challenges of incorporating big data applications into breast oncology research and clinical care, and to encourage the development of multidisciplinary collaborations that will apply big data technology to improve breast cancer treatment and the quality of health care delivery, and fuel scientific discovery to accelerate breakthroughs.

    On February 1-2, 2018, Komen will continue the big data conversation by convening the BD4BC3 conference to take a deeper dive into how big data can be leveraged toward Komen’s Bold Goal to reduce the current number of breast cancer deaths by 50% in the U.S. by 2026. he goals of this meeting are to leverage big data to identify breast cancer disparities and variances in care, and to improve the methods for aggregating and analyzing clinical, genomic and other sources of data for metastatic breast cancer patients. By focusing on these topics, we hope to map out strategies that will unlock big data to save lives.


    Planning Committee


    Amy Abernethy, M.D., Ph.D.
    Flatiron Health
    New York, NY

    Cheryl Jernigan, CPA, FACHE
    Komen Advocate in Science and Scientific Advisory Board
    Kansas City, MO

    Mia Levy, M.D., Ph.D.
    Vanderbilt-Ingram Cancer Center and Komen Scholar
    Nashville, TN

    Joshua Mann
    SHARE for Cures and Inspirata
    Washington, DC

    George Sledge, Jr., M.D.
    Stanford University and Komen’s Chief Scientific Advisor
    Palo Alto, CA


  • Questions?

    Send us a message